Daratumumab for a Patient With Refractory Antineutrophil Cytoplasmatic Antibody-Associated Vasculitis

Torben M Rixecker; Philipp M Lepper; Sebastian Mang; Pascal Espig; Katharina Brill; Lorenz Thurner; Joerg Thomas Bittenbring

doi:10.1001/jamainternmed.2023.0152

Daratumumab for a Patient With Refractory Antineutrophil Cytoplasmatic Antibody-Associated Vasculitis

JAMA Intern Med. 2023 Jun 1;183(6):615-618. doi: 10.1001/jamainternmed.2023.0152.

Authors

Torben M Rixecker¹, Philipp M Lepper¹, Sebastian Mang¹, Pascal Espig¹, Katharina Brill², Lorenz Thurner², Joerg Thomas Bittenbring²

Affiliations

¹ Department of Internal Medicine 5 (Pneumology, Allergology, and Intensive Care Medicine), Saarland University Medical School, Homburg, Germany.
² Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany.

No abstract available

Plain language summary

This case reports on a patient with antineutrophil cytoplasmatic antibody–associated vasculitis and severe pulmonary and cutaneous involvement who received conventional therapy that failed and who was rescued by daratumumab therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Monoclonal / therapeutic use
Humans

Substances

daratumumab
Antibodies, Monoclonal